
Arbutus Biopharma Corporation (Mon, Apr 29, 2024)

Hold candidate since Apr 29, 2024

StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania



score: **0.263** #7406/ 30074

rend:	Buy
IV Long:	Buy
IV Short:	Buy
Pivot:	Sell
olume:	Buy
IACD:	Sell

T N N P

V N

Tech commentaries:

The Arbutus Biopharma Corporation stock price gained 1.83% on the last trading day (Monday, 29th Apr 2024), rising from \$2.73 to \$2.78. During the last trading day the stock fluctuated 2.19% from a day low at \$2.74 to a day high of \$2.80. The price has fallen in 6 of the last 10 days and is down by -6.4% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 226 thousand more shares were traded than the day before. In total, 626 thousand shares were bought and sold for approximately \$1.74 million.

The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise **6.30%** during the next 3 months and, with a 90% probability hold a price between **\$2.70** and **\$3.37** at the end of this 3-month period.

The **Arbutus Biopharma Corporation** stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at **\$2.73** and **\$2.74**. A breakdown below any of these levels will issue sell signals. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on **Friday, April 05, 2024**, and so far it has fallen -10.90%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Arbutus Biopharma Corporation finds support from accumulated volume at \$2.76 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at \$2.92, \$3.00 and \$3.12.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved **\$0.0600** between high and low, or **2.19%**. For the last week, the stock has had daily average volatility of **2.53%**.

Arbutus Biopharma Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Risk: Medium

Evaluation: Hold/Accumulate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.